fda tirzepatide shortage update today facing blowback after ending of Mounjaro and Zepbound Tirzepatide, FDA, and Compounding: Understanding

Why Microdose

42 Notably, the discovery of RNA-dependent RNA polymerase and reverse transcriptase has been crucial for developing subsequent mRNA drugs

But what might ultimately play out is getting medicines working in tandem with endoscopy and metabolic surgery to help some people achieve even greater weight loss

Zhais team (Zhai et al., 2020) found that exendin-4, a GLP-1 receptor agonist, enhances eNOS activity and NO production, which helps relax retinal capillaries and restore microvascular perfusion in ischemia-reperfusion (I/R) injury models

CagriSema vs Comparators Feature Receptor targets CagriSema Amylin/calcitonin + GLP-1 Tirzepatide (Zepbound) GIP + GLP-1 Semaglutide alone (Wegovy) GLP-1 Cagrilintide alone Amylin/calcitonin (DACRA) Feature Dosing frequency CagriSema Once weekly Tirzepatide (Zepbound) Once weekly Semaglutide alone (Wegovy) Once weekly Cagrilintide alone Once weekly Feature Maintenance dose CagriSema 2.4 mg + 2.4 mg Tirzepatide (Zepbound) Up to 15 mg Semaglutide alone (Wegovy) 2.4 mg Cagrilintide alone 2.4 mg (in REDEFINE arms) Feature Headline weight loss CagriSema 20.4% at 68 wks (REDEFINE 1, treatment-policy) Tirzepatide (Zepbound) Up to 22.5% at 72 wks (SURMOUNT-1, 15 mg arm) Semaglutide alone (Wegovy) 14.9% at 68 wks (REDEFINE 1 reference arm) Cagrilintide alone 11.5% at 68 wks (REDEFINE 1 reference arm) Feature FDA status (June 2026) CagriSema NDA filed Dec 2025